Yeo lab:Projects
From OpenWetWare
| Line 4: | Line 4: | ||
|style="background:#ffffff"| | |style="background:#ffffff"| | ||
| - | One of the major obstacles in translating potent drug candidates from bench to bedside is delivery. For example, small interfering RNA (siRNA) has been recognized as a promising new class of drugs for viral infections, neurodegenerative diseases, and cancer; however, its therapeutic potential has not been realized because of the instability in circulation. Target-specific delivery of anti-cancer drugs with minimal side effects on normal tissues has long been a goal for cancer therapy, but their clinical application remains challenging. Research topics in my lab will focus on developing drug/gene delivery systems which can address these challenges in ‘delivery.’ Specific projects involve (i) addressing the obstacles in siRNA delivery using formulation approaches, (ii) developing nanoparticles which mimic leukocyte-rolling behavior for tumor targeting, and (iii) developing inhalable microparticles which allows for delivering combinations of drugs for cystic fibrosis therapy. | + | One of the major obstacles in translating potent drug candidates from bench to bedside is delivery. For example, small interfering RNA (siRNA) has been recognized as a promising new class of drugs for viral infections, neurodegenerative diseases, and cancer; however, its therapeutic potential has not been realized because of the instability in circulation. Target-specific delivery of anti-cancer drugs with minimal side effects on normal tissues has long been a goal for cancer therapy, but their clinical application remains challenging. Research topics in my lab will focus on developing drug/gene delivery systems which can address these challenges in ‘delivery.’ Specific projects involve (i) addressing the obstacles in siRNA delivery using formulation approaches, (ii) developing nanoparticles which mimic leukocyte-rolling behavior for tumor targeting, and (iii) developing inhalable microparticles which allows for delivering combinations of drugs for cystic fibrosis therapy. |
| - | + | ||
| - | + | ||
| - | + | ||
|}<br style="clear:both" /> | |}<br style="clear:both" /> | ||
Revision as of 23:48, 22 September 2006
Home Research Publications Lab Members Positions Contact Links Internal
|
One of the major obstacles in translating potent drug candidates from bench to bedside is delivery. For example, small interfering RNA (siRNA) has been recognized as a promising new class of drugs for viral infections, neurodegenerative diseases, and cancer; however, its therapeutic potential has not been realized because of the instability in circulation. Target-specific delivery of anti-cancer drugs with minimal side effects on normal tissues has long been a goal for cancer therapy, but their clinical application remains challenging. Research topics in my lab will focus on developing drug/gene delivery systems which can address these challenges in ‘delivery.’ Specific projects involve (i) addressing the obstacles in siRNA delivery using formulation approaches, (ii) developing nanoparticles which mimic leukocyte-rolling behavior for tumor targeting, and (iii) developing inhalable microparticles which allows for delivering combinations of drugs for cystic fibrosis therapy.
|
